Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1999 1
2003 1
2006 1
2007 1
2008 2
2009 2
2010 2
2011 2
2012 3
2013 2
2015 1
2016 2
2019 1
2020 2
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.
van de Loosdrecht AA, Cremers EMP, Alhan C, Duetz C, In 't Hout FEM, Visser-Wisselaar HA, Chitu DA, Verbrugge A, Cunha SM, Ossenkoppele GJ, Janssen JJWM, Klein SK, Vellenga E, Huls GA, Muus P, Langemeijer SMC, de Greef GE, Te Boekhorst PAW, Raaijmakers MHG, van Marwijk Kooy M, Legdeur MC, Wegman JJ, Deenik W, de Weerdt O, van Maanen-Lamme TM, Jobse P, van Kampen RJW, Beeker A, Wijermans PW, Biemond BJ, Tanis BC, van Esser JWJ, Schaar CG, Noordzij-Nooteboom HS, Jacobs EMG, de Graaf AO, Jongen-Lavrencic M, Stevens-Kroef MJPL, Westers TM, Jansen JH. van de Loosdrecht AA, et al. Among authors: deenik w. Leukemia. 2024 Apr;38(4):840-850. doi: 10.1038/s41375-024-02161-6. Epub 2024 Jan 31. Leukemia. 2024. PMID: 38297135 Free PMC article. Clinical Trial.
Thrombocytopenia in a nutshell.
Achterbergh R, Vermeer HJ, Curtis BR, Porcelijn L, Aster RH, Deenik W, Daemen-Gubbels C. Achterbergh R, et al. Among authors: deenik w. Lancet. 2012 Feb 25;379(9817):776. doi: 10.1016/S0140-6736(11)61643-7. Lancet. 2012. PMID: 22364760 Free PMC article. No abstract available.
MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.
Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Berenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST. Vermaat JS, et al. Among authors: deenik w. Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020. Haematologica. 2020. PMID: 31123031 Free PMC article.
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden AW, Deenik W, Gruber A, Coenen JL, Plesner T, Klein SK, Tanis BC, Szatkowski DL, Brouwer RE, Westerman M, Leys MR, Sinnige HA, Haukås E, van der Hem KG, Durian MF, Mattijssen EV, van de Donk NW, Stevens-Kroef MJ, Sonneveld P, Waage A. Zweegman S, et al. Among authors: deenik w. Blood. 2016 Mar 3;127(9):1109-16. doi: 10.1182/blood-2015-11-679415. Epub 2016 Jan 22. Blood. 2016. PMID: 26802176 Free article. Clinical Trial.
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Nielsen LK, Stege C, Lissenberg-Witte B, van der Holt B, Mellqvist UH, Salomo M, Bos G, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden A, Deenik W, Coenen J, Hinge M, Klein S, Tanis B, Szatkowski D, Brouwer R, Westerman M, Leys R, Sinnige H, Haukås E, van der Hem K, Durian M, Gimsing P, van de Donk N, Sonneveld P, Waage A, Abildgaard N, Zweegman S. Nielsen LK, et al. Among authors: deenik w. Haematologica. 2020 Jun;105(6):1650-1659. doi: 10.3324/haematol.2019.222299. Epub 2019 Sep 12. Haematologica. 2020. PMID: 31515355 Free PMC article. Clinical Trial.
Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.
Deenik W, van der Holt B, Janssen JJ, Chu IW, Valk PJ, Ossenkoppele GJ, van der Heiden IP, Sonneveld P, van Schaik RH, Cornelissen JJ. Deenik W, et al. Blood. 2010 Dec 23;116(26):6144-5; author reply 6145-6. doi: 10.1182/blood-2010-07-296954. Blood. 2010. PMID: 21183698 Free article. No abstract available.
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Thielen N, van der Holt B, Verhoef GE, Ammerlaan RA, Sonneveld P, Janssen JJ, Deenik W, Falkenburg JH, Kersten MJ, Sinnige HA, Schipperus M, Schattenberg A, van Marwijk Kooy R, Smit WM, Chu IW, Valk PJ, Ossenkoppele GJ, Cornelissen JJ. Thielen N, et al. Among authors: deenik w. Ann Hematol. 2013 Aug;92(8):1049-56. doi: 10.1007/s00277-013-1730-4. Epub 2013 Apr 10. Ann Hematol. 2013. PMID: 23572137 Clinical Trial.
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AV, Janssen JJ, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Westveer PH, Beverloo HB, Valk P, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ. Deenik W, et al. Blood. 2008 Mar 1;111(5):2581-8. doi: 10.1182/blood-2007-08-107482. Epub 2008 Jan 2. Blood. 2008. PMID: 18172005 Free article. Clinical Trial.
21 results